A Chinese medicine composition for promoting height growth and its preparation method and application

Abstract

The present invention provides a Chinese medicine composition for promoting height growth, and a preparation method and application thereof, which belong to the field of medical technology. The composition of the present invention is composed of Radix Dipsaci and Acanthopanax Senticosus in a mass ratio of 1-2:1-2. The preparation method of the Chinese medicine composition can be to obtain a medicinal liquid after decoction and filtration, or it can be an extract combination of raw materials. The Chinese medicine composition of the present invention can increase the proliferation rate of the proliferation zone of the growth plate chondrocytes, increase the number of cells in the proliferation zone, the prehypertrophic zone and the hypertrophic zone, and show an increase in the thickness of the growth plate, thereby promoting height growth.

Description

Technical Field

[0001] The invention belongs to the field of medical technology, and in particular relates to a Chinese medicine composition for promoting height growth, a preparation method and an application thereof. Background Art

[0002] Dwarfism refers to a person whose height is 2 standard deviations (-2SD) below the median height of children of the same gender and age or below the third percentile. The incidence rate in the population is about 3%. Its etiology is complex and the differential diagnosis range is wide. Recombinant human growth hormone (rhGH) or combined gonadotropin-releasing hormone (GnRH) agonist replacement therapy is the most commonly used clinical treatment measure for patients with dwarfism. However, excessive growth hormone treatment may increase growth rate and lead to rapid progression of puberty. Combined GnRH agonist treatment often leads to decreased bone density. In addition, long-term growth hormone injection treatment also has many potential risks of disease. Growth hormone is expensive, the injection method is inconvenient, and the clinical treatment effect varies greatly from person to person. Therefore, the development of Chinese medicine compound preparations with growth-promoting potential is feasible and has great prospects. At present, although the research on compound medicine for the treatment of dwarfism at home and abroad is based on the theory of Chinese medicine dialectical treatment, it lacks the material basis of efficacy and the molecular mechanism, which seriously limits the application and development of compound medicine for the clinical treatment of dwarfism. Summary of the invention

[0003] In view of this, the object of the present invention is to provide a traditional Chinese medicine composition for promoting height growth, which can increase the proliferation rate of chondrocytes in the proliferation zone of the growth plate, increase the number of cells in the proliferation zone, prehypertrophic zone and hypertrophic zone, and show an increase in the thickness of the growth plate, thereby promoting height growth.

[0004] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0005] The invention provides a traditional Chinese medicine composition for promoting height growth. The composition is composed of Dipsacus asper and Acanthopanax senticosus in a mass ratio of 1-2:1-2.

[0006] The invention provides a method for preparing the Chinese medicine composition, which comprises weighing raw materials according to the raw material ratio, decocting and filtering to obtain a medicinal solution.

[0007] The present invention also provides a method for preparing the above-mentioned traditional Chinese medicine composition, wherein the raw materials are weighed according to the raw material ratio, and the Dipsacus asper extract and the Acanthopanax senticosus extract are respectively extracted to obtain the Dipsacus asper extract and the Acanthopanax senticosus extract, and the extracts are mixed.

[0008] Preferably, the Dipsacus asper extract and Acanthopanax senticosus extract are Chinese patent medicine granules.

[0009] Preferably, the concentration of dipsaponin VI in the Dipsacus asper extract is ≥2 mg / mL, and the concentration of dipsaponin B is ≥30 μg / mL; the concentration of syringol glycoside in the Acanthopanax senticosus extract is ≥50 μg / mL, and the concentration of eleutheroside E is ≥80 μg / mL.

[0010] The present invention also provides the use of the above-mentioned traditional Chinese medicine composition in preparing a medicine for treating dwarfism.

[0011] Preferably, the Chinese medicine composition promotes the proliferation of tibial growth plate chondrocytes.

[0012] Preferably, the Chinese medicine composition promotes the formation of trabeculae.

[0013] The present invention also provides a medicine for treating dwarfism, which contains 0.1-100wt% of the above traditional Chinese medicine composition.

[0014] Preferably, the medicament comprises pharmaceutically acceptable excipients.

[0015] Beneficial effects of the present invention:

[0016] The Chinese medicine composition of the present invention can increase the proliferation rate of chondrocytes in the proliferation zone of the growth plate, thereby increasing the number of cells in the proliferation zone, the prehypertrophic zone and the hypertrophic zone to show an increase in the thickness of the growth plate, thereby promoting height growth. The Chinese medicine composition of the present invention can significantly increase the proliferation rate of ITS (insulin-transferrin-sodium selenite)-induced ATDC5 cells and promote the degree of chondrogenic differentiation of ITS-induced ATDC5 cells. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 : The effects of different Chinese medicine combinations on the serum IGF-1, LH, FSH and E2 levels of rats in each group;

[0018] Figure 2 :Effects of different Chinese medicine combinations on the development of tibial growth plate in rats of each group;

[0019] Figure 3 : The effects of different Chinese medicine combinations on tibial trabeculae in rats of each group;

[0020] Figure 4 : Effects of Dipsacus asper-Acanthopanax senticosus (XC) group on the growth of SD rats;

[0021] Figure 5 :Effects of Dipsacus asper-Acanthopanax senticosus (XC) group on ITS-induced chondrogenic proliferation of ATDC5 cells;

[0022] Figure 6 :Effects of Dipsacus asper-Acanthopanax senticosus (XC) group on chondrogenic differentiation of ATDC5 cells induced by ITS;

[0023] Figure 7 : Expression levels of Sox9, Col2a1, Acan, and Col10a1 genes during proliferation and differentiation of ATDC5 cells;

[0024] Figure 8 : Determination of the content of main active ingredients in the Dipsacus asper-Acanthopanax senticosus (XC) group. DETAILED DESCRIPTION

[0025] The invention provides a traditional Chinese medicine composition for promoting height growth. The composition is composed of Dipsacus asper and Acanthopanax senticosus according to the original medicinal materials mass ratio of 1-2:1-2, and the mass ratio is preferably 1:1.

[0026] Dipsacus asperWall.ex Henry, a Chinese herbal medicine, is the dried root of Dipsacus asperWall.ex Henry. It has the effects of nourishing the liver and kidney, strengthening tendons and bones, and promoting blood circulation. It is mainly used to treat liver and kidney deficiency, soreness of waist and knees, cold and dampness, metrorrhagia, restless fetus, traumatic injury, tendon and bone fracture, etc.

[0027] Acanthopanax senticosus, a Chinese medicine name. It is the rhizome or stem of Acanthapanax senticosus (Rupr.etmaxim) Harms, a plant of the Araliaceae family. It has the effects of invigorating qi and strengthening the spleen, nourishing the kidney and calming the mind. It is mainly used to treat spleen and lung qi deficiency, kidney deficiency, waist and knee pain, insomnia due to heart and spleen deficiency, forgetfulness, etc.

[0028] The present invention provides a method for preparing the above-mentioned traditional Chinese medicine composition: the method one can weigh the raw materials according to the raw material ratio, decoct and filter to obtain a medicinal liquid; as an optional implementation mode, the present invention weighs the raw medicinal materials of Dipsacus asper and Acanthopanax senticosus, and after processing with a traditional Chinese medicine grinder, weighs 15g of the raw medicinal material powder of each raw medicinal material for mixing, adds 1.8L of distilled water at a ratio of 1:60 between the material and the liquid, decocts at 100°C for 1.5h, and obtains the combined medicinal liquid of Dipsacus asper and Acanthopanax senticosus after filtering, which is set aside.

[0029] The second method can weigh the raw materials according to the raw material ratio, extract and obtain the Dipsacus asper extract and the Acanthopanax senticosus extract respectively, and mix the extracts; as an optional embodiment, the present invention takes the Dipsacus asper and the Acanthopanax senticosus raw medicinal materials, respectively processes them with a traditional Chinese medicine grinder, weighs the raw medicinal material powder, adds 300mL of distilled water at a ratio of 1:20 between the material and the liquid, extracts for 1h in a water bath at 80°C under the conditions of an ultrasonic power of 100W and an ultrasonic frequency of 40KHz, and obtains the Dipsacus asper extract or the Acanthopanax senticosus extract after filtering; the Dipsacus asper extract and the Acanthopanax senticosus extract are mixed and set aside.

[0030] Preferably, the extract of Radix Dipsaci and the extract of Acanthopanax senticosus of the present invention are Chinese patent medicine granules. As an optional embodiment, the Chinese patent medicine granules of Radix Dipsaci and Acanthopanax senticosus of the present invention are dissolved in double distilled water for use.

[0031] The concentration of dipsaponin VI in the Dipsacus asper extract of the present invention is required to be ≥2 mg / mL, and preferably, the concentration of dipsaponin VI is 2.5-5 mg / mL; the concentration of dipsaponin B is required to be ≥30 μg / mL, and preferably, the concentration of dipsaponin B is 35-60 μg / mL; the concentration of syringol glycosides in the Acanthopanax senticosus extract is required to be ≥50 μg / mL, and preferably, the concentration of syringol glycosides is 55-90 μg / mL; the concentration of eleutheroside E is required to be ≥80 μg / mL, and preferably, the concentration of eleutheroside E is 85-110 μg / mL.

[0032] The present invention also provides the use of the Chinese medicine composition in preparing a drug for treating dwarfism. The Chinese medicine composition promotes the proliferation of tibial growth plate chondrocytes and the formation of trabeculae.

[0033] The present invention also provides a medicine for treating dwarfism, the medicine containing 0.1-100wt% of the above Chinese medicine composition. The medicine of the present invention also includes pharmaceutically acceptable excipients, and the present invention does not limit the specific excipients.

[0034] As an optional embodiment, the content of the active ingredient of the drug for treating dwarfism of the present invention is calculated based on 35-45g of crude drug for 40kg of clinical children, preferably 40-41g of crude drug for 40kg of clinical children.

[0035] The technical solutions in the present invention will be described clearly and completely below in conjunction with the embodiments of the present invention. Obviously, the described embodiments are only a part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0036] In the following embodiments, the experimental animals are:

[0037] Sprague-Dawley (SD) rats, weighing 200-250 g, were purchased from Jinan Pengyue Experimental Animal Breeding Co., Ltd. (License No.: SCXK(Lu)20190003), and the experimental animals were allowed to eat and drink freely.

[0038] In the following embodiments, unless otherwise specified, all of them are conventional methods.

[0039] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.

[0040] Example 1

[0041] A Chinese medicine composition for promoting height growth, the composition is composed of Radix Dipsaci and Acanthopanax senticosus in a raw medicinal material mass ratio of 1:1. The preparation method is as follows: weigh 20g of Radix Dipsaci and Acanthopanax senticosus raw medicinal materials, weigh 15g of raw medicinal material powders after processing with a Chinese medicine grinder, mix them, add 1.8L of distilled water at a material-liquid ratio of 1:60, decoct at 100°C for 1.5h, filter through a filter to obtain a combined medicinal liquid of Radix Dipsaci and Acanthopanax senticosus, and set aside.

[0042] Example 2

[0043] A Chinese medicine composition for promoting height growth, the composition is composed of a granular preparation of Radix Dipsaci and a granular preparation of Acanthopanax senticosus according to the mass ratio of the original medicinal materials of 1:1. The preparation method is as follows: take the original medicinal material of Radix Dipsaci, after processing it with a Chinese medicine grinder, weigh 15g of the original medicinal material powder, add 300mL of distilled water at a ratio of 1:20 for the solid-liquid ratio, extract it in a water bath at 80°C for 1h under the conditions of ultrasonic power of 100W and ultrasonic frequency of 40KHz, and filter it to obtain a Radix Dipsaci extract; take the original medicinal material of Acanthopanax senticosus, after processing it with a Chinese medicine grinder, weigh 15g of the original medicinal material powder, add 300mL of distilled water at a ratio of 1:20 for the solid-liquid ratio, extract it in a water bath at 80°C for 1h under the conditions of ultrasonic power of 100W and ultrasonic frequency of 40KHz, and filter it to obtain an Acanthopanax senticosus extract; the Radix Dipsaci extract and the Acanthopanax senticosus extract are mixed for standby use.

[0044] Example 3

[0045] A Chinese medicine composition for promoting height growth, the composition is composed of a granule preparation of Radix Dipsaci and a granule preparation of Acanthopanax senticosus in a raw material weight ratio of 1:1. The preparation method is as follows: both Radix Dipsaci and Acanthopanax senticosus are granule preparations purchased from Jiangyin Tianjiang Pharmaceutical Co., Ltd., the raw material weight of each package of granule preparation is 15g, the concentration ratios of Radix Dipsaci and Acanthopanax senticosus granules are 4.95 times and 10.12 times respectively, and the dosage of each single herb is 1.5625g / kg, then 1.2624g Radix Dipsaci and 0.6176g Acanthopanax senticosus are weighed and dissolved in 40mL double distilled water in a ratio of 1:1 for standby use.

[0046] Comparative Example 1

[0047] A Chinese medicine composition, the composition is composed of Codonopsis pilosula and Acanthopanax senticosus in a raw material weight ratio of 1:1. The preparation method is as follows: Codonopsis pilosula and Acanthopanax senticosus are both granule preparations purchased from Jiangyin Tianjiang Pharmaceutical Co., Ltd., the raw material weight of each package of granule preparation is 15g, the concentration ratios of Codonopsis pilosula and Acanthopanax senticosus granules are 3.44 times and 10.12 times respectively, and the dosage of each single herb is 1.5625g / kg, then 1.816g Codonopsis pilosula and 0.6176g Acanthopanax senticosus are weighed and dissolved in 40mL double distilled water in a ratio of 1:1 for standby use.

[0048] Comparative Example 2

[0049] A Chinese medicine composition, the composition is composed of Codonopsis pilosula and Dipsacus root in a raw material weight ratio of 1:1. The preparation method is as follows: Codonopsis pilosula and Dipsacus root are both granule preparations purchased from Jiangyin Tianjiang Pharmaceutical Co., Ltd., the raw material weight of each package of granule preparation is 15g, the concentration ratios of Codonopsis pilosula and Dipsacus root granules are 3.44 times and 4.95 times respectively, and the dosage of each single herb is 1.5625g / kg, then 1.816g Codonopsis pilosula and 1.2624g Dipsacus root are weighed and dissolved in 40mL double distilled water in a ratio of 1:1 for standby use.

[0050] Comparative Example 3

[0051] A Chinese medicine composition, the composition is composed of Codonopsis pilosula, Dipsacus root and Acanthopanax senticosus according to the original medicinal material mass ratio of 1:1:1. The preparation method is as follows: Codonopsis pilosula, Dipsacus root and Acanthopanax senticosus are all granule preparations purchased from Jiangyin Tianjiang Pharmaceutical Co., Ltd., the original medicinal material mass of each package of granule preparation is 15g, the concentration ratios of Codonopsis pilosula, Dipsacus root and Acanthopanax senticosus granules are 3.44 times, 4.95 times and 10.12 times respectively, and the dosage of each single medicinal herb is 1.5625g / kg, then 1.816g Codonopsis pilosula, 1.2624g Dipsacus root and 0.6176g Acanthopanax senticosus are weighed and dissolved in 40mL double distilled water at a ratio of 1:1:1 for standby use.

[0052] Comparative Example 4

[0053] A Chinese medicine composition, the composition is composed of Codonopsis pilosula, Dipsacus root, Acanthopanax senticosus and Paeonia lactiflora in a raw material mass ratio of 1:1:1:1. The preparation method is as follows: Codonopsis pilosula, Dipsacus root, Acanthopanax senticosus and Paeonia lactiflora are all granule preparations purchased from Jiangyin Tianjiang Pharmaceutical Co., Ltd., the raw material mass of each package of granule preparation is 15g, the concentration ratios of Codonopsis pilosula, Dipsacus root, Acanthopanax senticosus and Paeonia lactiflora granules are 3.44 times, 4.95 times, 10.12 times and 7.16 times respectively, and the dosage of each single herb is 1.5625g / kg, then 1.816g Codonopsis pilosula, 1.2624g Dipsacus root, 0.6176g Acanthopanax senticosus and 0.8728g Paeonia lactiflora are weighed and dissolved in 40mL double distilled water in a ratio of 1:1:1:1 for standby use.

[0054] Example 4

[0055] 1. Experimental method: SD rats (healthy rats) were used as animal experimental subjects. The Chinese medicine compositions of Example 3 and Comparative Examples 1 to 4 were converted according to the clinical dosage standard (calculated according to the clinical dosage standard for children of 40 kg, 40 g of crude drug was given, and the dosage for rats was 6.25 g / kg. The rat experiment was performed according to the standard of 1 mL / 100 g) and then subjected to a single factor control experiment:

[0056] Control group (Control): The mice were intragastrically administered with the same amount of double distilled water as the drug-treated group.

[0057] Dipsacus asper-Acanthopanax senticosus (XC): the Chinese medicine composition described in Example 3.

[0058] Codonopsis pilosula-Acanthopanax senticosus (DC): the Chinese medicine composition described in Comparative Example 1.

[0059] Codonopsis pilosula-Dipsacus asper (DX): the Chinese medicine composition described in Comparative Example 2.

[0060] Codonopsis pilosula-Dipsacus asper-Acanthopanax senticosus (DXC): the Chinese medicine composition described in Comparative Example 3.

[0061] Codonopsis pilosula-Dipsacus asper-Acanthopanax senticosus-Red Peony Root (DXCC): the Chinese medicine composition described in Comparative Example 4.

[0062] SD rats were given drugs by continuous gavage for 4 weeks: Dipsacus-Acanthopanax (XC), Codonopsis-Acanthopanax (DC), Codonopsis-Dipsacus (DX), Codonopsis-Dipsacus-Acanthopanax (DXC), Codonopsis-Dipsacus-Acanthopanax-Red Peony Root (DXCC); each group was given drugs once a day by gavage, and the dose for each administration was 1 mL / 100 g.

[0063] 2. After 4 weeks of administration, the serum biochemical indexes and tibia of each group of rats were tested:

[0064] Comparison of serum biochemical indicators (IGF-1, LH, FSH, E2) of rats in each group. Figure 1 .Depend on Figure 1 It can be seen that compared with the control group, Dipsacus asper-Acanthopanax senticosus (XC), Codonopsis pilosula-Acanthopanax senticosus (DC), Codonopsis pilosula-Dipsacus asper (DX), Codonopsis pilosula-Dipsacus asper-Acanthopanax senticosus (DXC), Codonopsis pilosula-Dipsacus asper-Acanthopanax senticosus-Red Peony Root (DXCC) all showed a trend of increasing the serum IGF-1 level of rats and inhibiting the levels of FSH and LH, and there was no significant difference among the groups (p>0.05).

[0065] The development of tibial growth plate of rats in each group was compared. Figure 2 .Depend on Figure 2 It can be seen that compared with the control group, Codonopsis pilosula-Acanthopanax senticosus (DC) and Dipsacus asper-Acanthopanax senticosus (XC) can significantly promote the process of endochondral ossification of the proximal metaphyseal growth plate of the tibia in rats.

[0066] The morphology of tibia trabeculae in rats of each group was compared. Figure 3 .Depend on Figure 3 It can be seen that compared with the other groups, Dipsacus asper-Acanthopanax senticosus (XC) can significantly promote the formation of trabecular bone.

[0067] Depend on Figures 1 to 3 The results showed that X. scoparia-Acanthopanax senticosus (XC) had growth-promoting potential.

[0068] 3. Extend the oral administration time of the Dipsacus asper-Acanthopanax senticosus (XC) group and the control group (Control) to 6 weeks.

[0069] After 6 weeks, the effects of XC on the growth of SD rats were investigated. Figure 4 .Depend on Figure 4 It can be seen that compared with the normal control group, the body weight and body length of the rats in the XC combination preparation administration group showed a certain degree of increase, but there was no statistical significance (p>0.05). Although there was no significant change in body length and body weight, the number of chondrocytes in the proliferation zone, prehypertrophic zone and hypertrophic zone of the tibial growth plate in the XC treatment group was significantly increased, and the thickness of the growth plate was significantly increased, proving that the Dipsacus asper-Acanthopanax senticosus combination has obvious growth-promoting potential.

[0070] 4. Analysis of the effect of XC on ITS-induced chondrogenic differentiation of ATDC5 cells:

[0071] ITS-induced ATDC5 cells were used as an in vitro model to simulate endochondral ossification of the growth plate.

[0072] Weigh 1.2624g of Radix Dipsaci and 0.6176g of Acanthopanax senticosus and dissolve them in 40mL of double distilled water to prepare the XC solution of the in vivo animal experiment dose, and set aside. DMEM-Ham's F12 cell culture medium was used to dilute XC by 20 times, 100 times, 500 times, 1000 times, and 2000 times, and CCK-8 was used to detect cell activity to preliminarily determine that the dose range of XC cell experiment was 100-1000 times. The cell dose of the Radix Dipsaci-Acanthopanax combination preparation was further designed to be diluted 125-1000 times: the low dose group (LD) was diluted 1000 times; the medium dose group (MD) was diluted 500 times; the high dose group (HD) was diluted 250 times; and the very high dose group (VHD) was diluted 125 times.

[0073] CCK-8 and crystal violet staining were used to investigate the effects of XC combination preparations on ITS-induced ATDC5 cell chondrogenesis. Figure 5 . Figure 5 The results of CCK-8 experiments showed that XC significantly increased the proliferation of ITS-induced ATDC5 cells in a concentration-dependent manner. Crystal violet staining on the 7th day of induction clearly showed that the XC combination preparation promoted the proliferation of ITS-induced ATDC5 cells, indicating that the treatment with the Dipsacus asper-Acanthopanax senticosus combination preparation (125-fold dilution) could significantly increase the proliferation rate of ITS-induced ATDC5 cells.

[0074] ATDC5 cells were stained with Alcian blue and Alizarin red to investigate the effect of XC combination preparation on ITS-induced chondrogenic differentiation of ATDC5 cells. Figure 6 . Figure 6 The results of Alcian blue staining and Alizarin red staining showed that the staining of ATDC5 cells treated with ITS and XC (extremely high dose) for 7, 14 and 21 days was significantly deeper than that of ITS alone, indicating that the proteoglycan secretion and calcium nodule formation of ATDC5 cells increased significantly after XC treatment. Therefore, XC can significantly promote the degree of chondrogenic differentiation of ITS-induced ATDC5 cells at 21 days.

[0075] The total RNA samples of each group of cells on days 0, 7, 14 and 21 were extracted by Trizol method and reverse transcribed into cDNA. GAPDH was used as the internal reference gene and SYBR Green qPCR was used to detect the changes in the expression levels of marker genes such as Sox9, Col2a1, Acan and Col10a1 during the ITS-induced chondrogenic differentiation of ATDC5 cells. The results are shown in Figure 7 It was found that XC (extremely high dose) treatment did not affect the mRNA expression levels of marker genes in the 21-day differentiation process of cells, indicating that the combination preparation of Dipsacus asper-Acanthopanax senticosus may increase the proliferation rate of growth plate chondrocyte proliferation zone, increase the number of cells in this area, prehypertrophic zone and hypertrophic zone, and show an increase in growth plate thickness, thereby realizing the potential of promoting growth.

[0076] Example 5

[0077] The concentrations of eugenol glycosides and eleutheroside E in the combined preparation of Dipsacus asper and Acanthopanax senticosus in Example 3 were determined by RP-HPLC. Standard curves were established with eugenol glycosides and eleutheroside E standards, respectively. An appropriate amount of the mixed sample was weighed and placed in a conical flask, filtered through a 0.45 μm microporous filter, and the concentrations of eugenol glycosides and eleutheroside E were determined by the machine, which were 67.70 μg / mL and 94.25 μg / mL, respectively. The concentrations of Dipsacus asper saponin VI and Dipsacus asper saponin B in the combined preparation of Dipsacus asper and Acanthopanax senticosus were determined by UPLC-MS / MS. Standard curves were established with Dipsacus asper saponin VI and Dipsacus asper saponin B standards, respectively. An appropriate amount of sample was accurately weighed in a centrifuge tube, vortexed with water, and ultrasonically extracted and centrifuged. After the supernatant was filtered through a 0.22 μm microporous filter, the concentrations of saponin VI and Dipsacus asper saponin B were detected by the machine, which were 45.35 μg / mL and 3.99 mg / mL, respectively. The results are shown in Table 1. Figure 8 .Depend on Figure 8 It can be seen that in the Dipsacus asper-Acanthopanax combination preparation of Example 3, the concentration of Dipsacus asper saponin VI is ≥2 mg / mL, the concentration of Dipsacus asper saponin B is ≥30 μg / mL, the concentration of syringol glycoside is ≥50 μg / mL, and the concentration of Acanthopanax aspergillus glycoside E is ≥80 μg / mL.

[0078] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A Chinese medicine composition for promoting the proliferation of tibial growth plate chondrocytes and / or promoting trabecular formation, characterized in that: The raw materials used to prepare the composition are composed of Dipsacus asper and Acanthopanax senticosus in a mass ratio of 1:1; The preparation method of the Chinese medicine composition is: Weigh the raw materials of Dipsacus asper and Acanthopanax senticosus according to the raw material ratio, mix them after processing with a traditional Chinese medicine grinder, add distilled water at a ratio of 1g:60mL, boil them at 100°C for 1.5h, and filter them through a filter to obtain a combined medicinal liquid of Dipsacus asper and Acanthopanax senticosus; or, Take the raw medicinal materials of Radix Dipsaci and Acanthopanax senticosus, process them respectively with a traditional Chinese medicine grinder, weigh the raw medicinal material powder according to the raw material ratio, add distilled water at a ratio of 1g:20mL of solid-liquid ratio, extract at 80°C in a water bath for 1h under the conditions of ultrasonic power of 100W and ultrasonic frequency of 40KHz, and obtain the Radix Dipsaci extract or Acanthopanax senticosus extract after filtering; mix the Radix Dipsaci extract with the Acanthopanax senticosus extract; or, The Dipsacus asper and Acanthopanax senticosus are both granule preparations.

2. Use of the Chinese medicine composition according to claim 1 in preparing a drug for treating dwarfism.

Images